Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on May 28, 2014 4:13pm
253 Views
Post# 22607117

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Lack of communications

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Lack of communicationsHi Jkj.

Yes, there are all of these very positive things like new offices, Dr Peter Johann's positive announcement re rvx-208 and the more positive statement from the CC that signal this comapny is in business for the long term.

Don obviously has the support of the board but this may not mean much if Eastern doesn't have a seat. However, it's seems like KD is in support of him and that reassures me. At least he hasn't moved in in a hostile way. NGN Capital is on the board. So there is pretty good company and expertise.

Somebody has to fund the trial. KD apparently has not stepped up to the plate. AZ needs something like rvx-208 in a very,very big way and it would be a huge victory for them or Phfizer, IMO. If AZ stepped in with a CVR then KD would benefit almost immediately and I don't think he would allow the initial payment to be low. He would at least want to break even. Then he can kick back at a break even investment and make millions on the on each of the hurdle point payouts.

Also, he still has all of his Zenith shares and we all know how hot epigenitics is these days.

As much as I'm frustrated by the lack of communication, and am waivering, I'm still holding my postion on the basis that they can't communicate because they are deal making.

Cheers
Toinv


Bullboard Posts